top of page

Food-Responsive Enteropathy in Dogs: Nutritional Strategies and Evidence Interpretation

 

VetFarmacy Clinical Evidence Library

Body System: Gastrointestinal Nutrition

Author: Dr. Athena Angela Gaffud, DVM

Content Type: Condition Evidence Overview

Evidence Base: Peer-reviewed veterinary and translational literature synthesis

Last Reviewed: 2026

Purpose: Evidence-based synthesis of current veterinary and translational literature evaluating nutritional strategies in food-responsive enteropathy in dogs

Evidence Transparency

 

This article synthesizes findings from peer-reviewed veterinary clinical trials, retrospective cohort studies, microbiome research, nutritional intervention studies, and translational literature related to the pathophysiology and nutritional management of food-responsive enteropathy (FRE) in dogs.

​

Because FRE represents a heterogeneous subset of chronic inflammatory enteropathies, the available evidence includes randomized controlled dietary trials, observational studies, elimination-diet investigations, biomarker studies, and mechanistic research examining intestinal inflammation, epithelial barrier dysfunction, microbiome alterations, bile acid metabolism, nutrient digestibility, and immune-mediated responses to dietary antigens.

​

Where direct clinical evidence is limited, mechanistic and translational data are used to interpret nutritional strategies involving hydrolyzed diets, elemental diets, fiber modulation, microbiome-targeted interventions, and functional nutritional ingredients.

​

Distinctions are made between:

​

  • Strong evidence: randomized controlled trials, controlled dietary intervention studies, and long-term outcome analyses

  • Emerging evidence: microbiome modulation, metabolomic biomarkers, postbiotics, functional fibers, and adjunctive nutritional therapies

  • Extrapolated evidence: mechanistic gastrointestinal immunology, comparative inflammatory bowel disease research, and cross-species metabolic data

 

This content is intended for educational interpretation of veterinary nutrition research and does not replace individualized veterinary medical care.

Introduction

 

Food-responsive enteropathy (FRE) is a subset of chronic enteropathy in dogs characterized by persistent gastrointestinal signs—typically diarrhea, vomiting, weight loss, or altered stool quality—that resolve with dietary modification alone. It is considered part of the broader chronic inflammatory enteropathy spectrum, alongside antibiotic-responsive and immunosuppressant-responsive forms, but is distinguished by its primary responsiveness to nutritional intervention.

​

Within the clinical framework of VetFarmacy, FRE is a condition in which diet functions as both a diagnostic tool and a therapeutic intervention, making nutritional strategy central to disease resolution rather than supportive care.

​

From a disease-burden perspective, chronic enteropathies are common in small-animal practice, with FRE accounting for a substantial proportion of cases and often demonstrating favorable long-term outcomes when appropriately managed (Allenspach et al., 2016; Dandrieux & Mansfield, 2019).

​

For a broader systems-level overview, see:
https://www.vetfarmacy.com/canine-health/gastrointestinal-system

​

Mechanistic understanding of digestion and nutrient handling is foundational to interpreting FRE:
https://www.vetfarmacy.com/evidence-library/digestibility-and-nutrient-absorption-in-dogs

​

Pathophysiology of Food-Responsive Enteropathy

 

FRE is best understood as an interplay among dietary antigens, intestinal barrier function, immune signaling, and microbiome composition, leading to localized gastrointestinal inflammation.

​

Inflammation and Immune Signaling

 

Dietary proteins that are insufficiently digested can act as antigens, triggering mucosal immune activation. Histopathological findings often include lymphoplasmacytic infiltration, indicating chronic immune stimulation (Walker et al., 2013).

​

This immune response alters cytokine signaling pathways and promotes low-grade intestinal inflammation, which contributes to clinical signs.

​

Metabolic Dysfunction

 

Chronic inflammation disrupts nutrient absorption and alters intestinal metabolism. Changes in amino acid profiles and short-chain fatty acid (SCFA) production reflect impaired metabolic homeostasis (Higueras et al., 2023; Higueras et al., 2021).

​

These metabolic changes influence epithelial turnover, energy utilization, and overall digestive efficiency.

​

Cellular Injury and Barrier Dysfunction

 

Compromised intestinal epithelial integrity increases permeability (“leaky gut”), allowing further translocation of antigens and perpetuating inflammation.

​

Lipids and Oxidative Stress

 

Altered lipid metabolism contributes to inflammatory signaling. Changes in bile acid metabolism and lipid-derived mediators influence mucosal immunity and microbiome composition (Wang et al., 2019).

​

Oxidative stress further exacerbates epithelial injury and inflammatory cascades. 

​

Food-responsive enteropathy is increasingly understood within the updated classification of chronic inflammatory enteropathies, which emphasizes response-to-treatment categories rather than purely histopathologic definitions. This framework recognizes FRE as a distinct clinical phenotype characterized by diet-induced remission without the need for antibiotics or immunosuppressive therapy (Dupouy-Manescau et al., 2024; Allenspach & Mochel, 2021).

​

At the biomarker level, FRE is associated with measurable alterations in intestinal and systemic inflammatory and metabolic indices. Changes in serum and fecal amino acid profiles reflect impaired nutrient assimilation and epithelial turnover, while alterations in short-chain fatty acids and lipid metabolites indicate shifts in microbial fermentation and energy metabolism (Higueras et al., 2023; Higueras et al., 2021).

​

Additional exploratory biomarkers, including circulating endocannabinoids and vitamin D status, suggest broader systemic involvement of immune-metabolic signaling pathways in chronic enteropathies (Febo et al., 2021; Vecchiato et al., 2025).

​

These findings support a model in which FRE is not solely a localized intestinal disorder, but a multifactorial condition involving immune dysregulation, microbial imbalance, and metabolic disturbance, all of which are modifiable through targeted nutritional intervention.

​

An additional mechanistic layer involves disruption of the intestinal microbiome–bile acid axis, which plays a central role in regulating inflammation, epithelial function, and nutrient metabolism. In dogs with food-responsive enteropathy, diet-induced remission has been associated with significant shifts in microbial community structure and increased production of secondary bile acids, which exert anti-inflammatory and regulatory effects on intestinal immunity (Wang et al., 2019).

​

Alterations in bile acid metabolism influence signaling through receptors such as FXR and TGR5, which modulate epithelial barrier integrity, immune responses, and lipid metabolism. Dysregulation of this system may contribute to persistent inflammation and impaired resolution in chronic enteropathy.

​

These findings reinforce that dietary intervention in FRE does not simply remove antigen exposure but actively reshapes microbial metabolism and host signaling pathways, contributing to sustained clinical remission.

​

Nutritional Risk Factors

 

Dietary patterns play a central role in both the development and persistence of chronic enteropathies.

​

Macronutrient Imbalance

 

Excessive or poorly digestible protein increases luminal antigen exposure, while imbalanced macronutrient ratios can disrupt microbial fermentation patterns.

​

Fat Composition

 

High-fat diets may alter bile acid metabolism and microbiome composition, contributing to inflammation and diarrhea in susceptible dogs.

​

Ultra-Processed Diets

 

Highly processed diets may influence disease risk through reduced nutrient bioavailability and altered interactions with the microbiome.

​

Relevant evidence: https://www.vetfarmacy.com/evidence-library/ultra-processed-vs-minimally-processed

 

Epidemiologic studies suggest early-life diet composition influences later risk of chronic enteropathy (Vuori et al., 2023; Trewin & Kathrani, 2023).

​

Retrospective and prospective studies further demonstrate that dietary history is a significant predictor of disease development and treatment response. Dogs exposed to highly processed or compositionally inconsistent diets during early life stages may exhibit increased susceptibility to chronic enteropathies later in life, potentially due to altered immune tolerance and microbiome development (Vuori et al., 2023).

​

In addition, dietary antigen diversity and prior exposure patterns influence the likelihood of successful response to elimination diets. Dogs with extensive exposure to multiple protein sources may demonstrate reduced responsiveness to novel protein strategies, necessitating hydrolyzed or elemental approaches (Trewin & Kathrani, 2023).

​

Clinical cohort analyses also suggest that breed, diet composition, and disease chronicity interact to influence outcomes, reinforcing the importance of individualized dietary planning in FRE (Candellone et al., 2024).

​

Longitudinal data further indicate that lifetime dietary exposure patterns influence both disease susceptibility and treatment response. Dogs exposed to a wide variety of protein sources over time may develop broader antigen sensitization, reducing the effectiveness of novel protein elimination strategies and increasing reliance on hydrolyzed or elemental diets (Trewin & Kathrani, 2023).

​

Conversely, controlled and consistent dietary exposure during early life may support immune tolerance and reduce the risk of chronic enteropathy development, suggesting a role for nutritional programming of immune function (Vuori et al., 2023).

​

These observations highlight that dietary risk in FRE is not limited to current feeding practices but reflects cumulative exposure and immune conditioning over time, which must be considered when selecting diagnostic and therapeutic diets.

​

Evidence-Based Nutritional Strategies

​

Fat

 

Mechanism: Dietary fat influences bile acid secretion, lipid metabolism, and inflammatory signaling.


Clinical relevance: In subsets of chronic enteropathy—particularly protein-losing enteropathy—fat restriction may improve clinical outcomes (Myers et al., 2023).


Evidence classification: Emerging evidence (condition-dependent).

 

Although fat restriction is not universally required in FRE, subsets of dogs—particularly those with protein-losing enteropathy or concurrent lipid intolerance—may benefit from reduced dietary fat intake. Low-fat diets can decrease lymphatic flow and intestinal lipid transport, potentially reducing protein loss and improving clinical stability (Myers et al., 2023; Rudinsky et al., 2017).

​

In addition, dietary fat composition influences the production of inflammatory lipid mediators. Diets enriched in certain fatty acid profiles may modulate eicosanoid pathways and immune signaling, although clinical evidence specific to FRE remains limited.

​

These findings suggest that fat modification should be considered case-dependent, particularly in dogs with severe enteropathy or evidence of lipid-associated intolerance.

​

Protein

 

Mechanism: Intact dietary proteins can act as antigens; hydrolyzed proteins reduce antigenicity by decreasing peptide size.
Clinical relevance: Hydrolyzed or novel protein diets are central to elimination trials and remission induction in FRE.


Evidence:

​

Evidence classification: Strong evidence.

 

Hydrolyzed protein diets have been consistently associated with clinical remission in dogs with FRE across both controlled trials and real-world clinical settings. In randomized and field studies, hydrolyzed diets significantly improve clinical activity indices, stool quality, and histopathologic inflammation scores (Mandigers et al., 2010; Simpson et al., 2023).

​

Importantly, hydrolyzed diets also serve as diagnostic tools, allowing clinicians to confirm food responsiveness by assessing symptom resolution during elimination trials (Yeo, 2017).

​

In more refractory cases, elemental diets, which provide amino acids in their simplest form, have demonstrated efficacy in inducing remission where hydrolyzed or novel protein diets have failed (Manchester et al., 2023; Tinsley et al., 2023).

​

Emerging research into alternative protein sources, including insect-based proteins, suggests potential roles in reducing antigen exposure while maintaining nutritional adequacy, although clinical data remain limited (Gałęcki et al., 2024).

​

Carbohydrates / Fiber

 

Mechanism: Fiber modulates microbial fermentation, SCFA production, and stool consistency.


Clinical relevance: Balanced fiber supports microbiome stability and improves stool quality.


Evidence: Fiber supplementation improves outcomes in chronic GI disease (Moreno et al., 2022; Jackson & Jewell, 2018).

​

Evidence classification: Strong evidence (functional fiber use).

​

The balance between saccharolytic and proteolytic fermentation is a critical determinant of intestinal health. Diets that promote saccharolytic fermentation increase production of beneficial SCFAs such as butyrate, which support epithelial integrity and anti-inflammatory signaling. Conversely, excessive proteolytic fermentation can produce metabolites associated with mucosal irritation and inflammation (Jackson & Jewell, 2018).

​

Clinical studies demonstrate that fiber-enriched diets, particularly those containing fermentable fiber blends, can improve stool consistency and reduce clinical signs in dogs with chronic enteropathy (Fritsch et al., 2022).

​

These findings highlight the importance of fiber type, fermentability, and inclusion level in shaping microbiome composition and functional output.

​

Micronutrients

 

Mechanism: Vitamins and minerals support epithelial integrity, immune regulation, and oxidative balance.


Clinical relevance: Deficiencies (e.g., vitamin D) correlate with disease severity (Vecchiato et al., 2025).

​

Evidence classification: Emerging evidence.

 

Micronutrient status is increasingly recognized as both a marker and modulator of disease severity in chronic enteropathies. Deficiencies in fat-soluble vitamins, particularly vitamin D, have been associated with altered immune function and worse clinical outcomes, suggesting a link between micronutrient metabolism and disease progression (Vecchiato et al., 2025).

​

In addition, chronic intestinal inflammation may impair the absorption of essential vitamins and minerals, further contributing to metabolic dysfunction and delayed recovery.

​

Emerging evidence also suggests that targeted micronutrient support may help restore epithelial integrity and immune balance, although controlled clinical trials in FRE are limited (Tamura, 2025).

​

This positions micronutrient management as an adjunctive but clinically relevant component of nutritional strategy.

​

Functional Ingredients in Food-Responsive Enteropathy

​

 

Prebiotic and synbiotic interventions have also been investigated in FRE, with mixed results. While some studies demonstrate improvements in clinical indices and intestinal gene expression, others show minimal impact on microbiome diversity, suggesting that host response variability plays a significant role in therapeutic outcomes (Schmitz et al., 2015; Pilla et al., 2019).

​

Additionally, combinations of dietary fiber and probiotics have been associated with rapid clinical improvement in large bowel diarrhea, indicating potential synergistic effects on microbiome modulation (Rossi et al., 2020).

​

Overall, these interventions are best considered adjunctive strategies rather than primary treatments, with their role dependent on individual patient response.

​

Dietary Approaches

 

Dietary strategies in FRE include:

​

  • Hydrolyzed protein diets

  • Novel protein elimination diets

  • Elemental diets

  • Highly digestible formulations

 

Hydrolyzed diets remain the most commonly used first-line approach due to their ability to reduce antigen exposure while maintaining nutritional adequacy (Kathrani, 2020).

​

Fresh and minimally processed diets may influence digestibility and microbiome composition, but evidence remains heterogeneous.

​

Comparative studies indicate that dietary intervention alone can achieve remission in a substantial proportion of dogs with chronic enteropathy, often exceeding the efficacy of pharmacologic therapy in food-responsive cases (Rodrigues et al., 2025).

​

Long-term follow-up data demonstrate that dogs responding to dietary therapy alone tend to have more favorable prognoses compared to those requiring immunosuppressive treatment, highlighting the importance of early dietary intervention (Allenspach et al., 2016).

​

However, not all cases respond uniformly. Dogs with more severe disease, including protein-losing enteropathy, may require combined dietary and medical management and may exhibit variable responses depending on diet composition and disease chronicity (Margrey et al., 2025; Hodel et al., 2024).

​

These findings reinforce that diet selection is both a therapeutic intervention and a stratification tool, helping identify disease subtype and guide escalation pathways.

​

Comparative clinical data indicate that different dietary strategies vary in both speed of response and long-term remission rates. Hydrolyzed diets are generally associated with rapid improvement in clinical signs, often within 2–4 weeks, while novel protein diets may require longer adaptation periods and show more variable outcomes depending on prior dietary exposure (Ing & Steiner, 2024).

​

Elemental diets, although less commonly used, provide the highest level of antigen exclusion and may be effective in refractory cases where both hydrolyzed and novel protein strategies have failed (Manchester et al., 2023).

​

Importantly, failure to respond to one dietary strategy does not exclude dietary responsiveness altogether, but may instead reflect incomplete antigen elimination or suboptimal nutrient composition, necessitating iterative dietary trials.

​

Clinical Outcomes and Evidence Summary

 

Clinical outcomes in FRE are closely tied to dietary responsiveness and disease classification.

​

Strong evidence:

​

  • Hydrolyzed protein diets induce remission in a significant proportion of cases

  • Elimination diet trials provide both diagnostic confirmation and therapeutic benefit

  • Dietary intervention alone is sufficient in many dogs with FRE

 

Long-term outcome studies indicate that dogs with food-responsive enteropathy generally have favorable prognoses, particularly when early dietary intervention is implemented. However, relapse can occur if dietary compliance is inconsistent or if underlying sensitivities are not fully addressed (Allenspach et al., 2016).

​

Risk factors for poorer outcomes include severe clinical presentation, hypoalbuminemia, and delayed response to dietary therapy, which may indicate transition to more complex forms of chronic enteropathy requiring multimodal management (Allenspach et al., 2007).

​

These findings emphasize that response to diet is both a therapeutic endpoint and a prognostic indicator in FRE.

​

Emerging evidence:

​

  • Microbiome modulation influences treatment response and remission stability

  • Biomarkers such as SCFAs and amino acid profiles may predict response

​

Extrapolated evidence:

​

  • Mechanistic parallels with human inflammatory bowel disease

  • Role of lipid metabolism and immune signaling in chronic inflammation

​

Relevant evidence resources:

https://www.vetfarmacy.com/evidence-library/inflammation-and-nutritional-modulation
https://www.vetfarmacy.com/evidence-library/gut-microbiome-and-digestive-health

​

Clinical Decision Support

 

Dietary intervention is both a diagnostic and therapeutic step in FRE.

​

Hydrolyzed diets are typically first-line, with escalation to elemental diets or adjunct therapies in refractory cases. Novel protein diets may be appropriate depending on dietary history.

​

To compare structured approaches: https://www.vetfarmacy.com/decision-frameworks/low-fat-hydrolyzed-fresh-diet

VetFarmacy Clinical Resource

 

Readers who want a structured overview of how veterinarians evaluate diet strategies for chronic gastrointestinal disease can access the VetFarmacy clinical guide:

​

Veterinary Diet Decision Framework for Dogs

 

This evidence-based reference explains how veterinarians match diet strategies to underlying disease mechanisms, including chronic enteropathy, food-responsive gastrointestinal disease, pancreatitis, food allergy, obesity, kidney disease, and joint disorders.

​

The guide summarizes:

​

  • how highly digestible diets reduce gastrointestinal workload

  • when hydrolyzed diets are used diagnostically

  • why fat restriction matters in selected digestive conditions

  • how veterinarians compare low-fat, hydrolyzed, fresh, and therapeutic diet strategies

  • how diet decisions are individualized based on disease severity, clinical response, age, activity level, and medical history

​​

The framework also includes:

​

  • gastrointestinal diet strategy models

  • hydrolyzed vs novel protein comparisons

  • veterinary nutrition evidence hierarchy

  • diet decision flowcharts used in clinical reasoning

​

What to Feed: Translating Evidence Into Practice

 

Diet selection should be guided by the underlying disease mechanisms, clinical severity, and individual response to previous dietary interventions. The options below summarize how different dietary strategies are typically applied in clinical practice.

 

Pathway 1: Hydrolyzed Diets

 

Use when:
Chronic or unexplained gastrointestinal signs persist
Food-responsive enteropathy is suspected
Cutaneous adverse food reactions are possible

​

Clinical rationale:
Hydrolyzed diets reduce antigen exposure and are commonly used in elimination diet trials to identify food-related disease.

Compare hydrolyzed diet options for this condition.

 

Pathway 2: Low-Fat Diets

 

Use when:
Fat-sensitive conditions are present
History of lipid intolerance

 

Clinical rationale:
Reducing dietary fat may improve tolerance in subsets of gastrointestinal disease.

Compare low-fat diet options for this condition.

 

Pathway 3: Fresh / Minimally Processed Diets

 

Use when:
Appetite is reduced
Long-term compliance is a concern

 

Clinical rationale:
Fresh diets may improve palatability and intake.

Explore fresh diet options for this condition.

​

How to Choose Between These Options

 

For acute or severe presentations → controlled therapeutic diets are preferred
For chronic or unresolved cases → elimination diets are indicated
For long-term management → diet selection depends on tolerance and response

​

Key Takeaways

 

Food-responsive enteropathy: Diet-responsive chronic inflammatory GI disease
Hydrolyzed diets: Primary diagnostic and therapeutic strategy
Microbiome: Central to disease modulation
Inflammation: Driven by antigen exposure and barrier dysfunction
Clinical nutrition: Core component of management

​

Evidence Notes

 

Strong evidence: Randomized controlled trials and cohort studies support the efficacy of hydrolyzed diets and elimination trials as primary interventions in FRE.

Emerging evidence: Microbiome-targeted therapies, functional ingredients, and metabolic biomarkers are under active investigation but lack consistent clinical validation.

Extrapolated evidence: Comparisons with human inflammatory bowel disease provide mechanistic insight but must be interpreted cautiously, given species differences.

Limitations: Heterogeneity in study design, diet composition, and outcome measures complicates direct comparison across studies. Many trials are small-scale or uncontrolled, and long-term data remain limited.

​

A critical limitation across the evidence base is the lack of standardization in dietary formulations, which makes direct comparisons between studies challenging. Variability in protein source, degree of hydrolysis, fiber composition, and fat content introduces confounding factors that influence outcomes.

​

In addition, many studies rely on clinical response rather than objective biomarkers as primary endpoints, which may overestimate efficacy in some cases.

​

Future research should prioritize controlled, comparative trials with standardized dietary compositions and incorporation of validated biomarkers to improve the precision of nutritional recommendations in FRE.

VetFarmacy Clinical Resource

 

VetFarmacy publishes downloadable veterinary nutrition interpretation guides designed to help readers understand how dietary decisions are made in clinical practice.

​

Veterinary Diet Decision Framework for Dogs

​

This clinical resource explains how veterinarians select dietary strategies based on:

​

  • gastrointestinal disease mechanisms

  • inflammation and digestive tolerance

  • food-responsive enteropathy and elimination diet trials

  • microbiome and nutrient interaction

  • fat sensitivity and nutrient digestibility

  • metabolic and immune-mediated disease processes

 

The guide includes:

  • digestive diet strategy frameworks

  • hydrolyzed versus novel protein comparisons

  • veterinary diet decision flowcharts

  • diet type comparison matrices

  • veterinary nutrition evidence hierarchy models

  • practical questions veterinarians use when evaluating long-term diet plans

 

Subscribers receive access to current and future VetFarmacy clinical nutrition resources as they are released.

Featured resource: Veterinary Diet Decision Framework for Dogs: Evidence-Based Selection Guide by Dr. Athena Angela DLC Gaffud, DVM.

​References

​

  • Allenspach, K., Culverwell, C., & Chan, D. (2016). Long-term outcome in dogs with chronic enteropathies: 203 cases. Veterinary Record, 178, 368–368. https://doi.org/10.1136/vr.103557

  • Allenspach, K., & Mochel, J. (2021). Current diagnostics for chronic enteropathies in dogs. Veterinary Clinical Pathology. https://doi.org/10.1111/vcp.13068

  • Allenspach, K., Wieland, B., Gröne, A., & Gaschen, F. (2007). Chronic enteropathies in dogs: Evaluation of risk factors for negative outcome. Journal of Veterinary Internal Medicine, 21(4), 700–708. https://doi.org/10.1892/0891-6640(2007)21[700:ceideo]2.0.co;2

  • Borella, F., Benvenuti, E., Pierini, A., Borrelli, A., Cagnasso, F., Zanatta, R., Marchetti, V., & Gianella, P. (2025). Retrospective evaluation of short- and medium-term therapeutic response to different immunosuppressive and dietary approaches in 148 dogs diagnosed with immunosuppressant-responsive enteropathy. Open Veterinary Journal, 15, 4470–4481. https://doi.org/10.5455/ovj.2025.v15.i9.53

  • Bresciani, F., Minamoto, Y., Suchodolski, J. S., Galiazzo, G., Vecchiato, C., Pinna, C., Biagi, G., & Pietra, M. (2018). Effect of an extruded animal protein-free diet on fecal microbiota of dogs with food-responsive enteropathy. Journal of Veterinary Internal Medicine, 32, 1903–1910. https://doi.org/10.1111/jvim.15227

  • Candellone, A., Raviri, G., Saettone, V., Didier, M., Rossi, G., Marchegiani, A., Gavazza, A., Di Cerbo, A., & Cerquetella, M. (2024). Retrospective study of 222 dogs suffering from food-responsive enteropathy—Correlation with clinical variables, diet and breed. Veterinary Sciences, 11. https://doi.org/10.3390/vetsci11070294

  • Cline, M. (2016). A systematic approach to nutritional management of gastrointestinal disease.

  • Dandrieux, J. (2016). Inflammatory bowel disease versus chronic enteropathy in dogs: Are they one and the same? Journal of Small Animal Practice, 57(11), 589–599. https://doi.org/10.1111/jsap.12588

  • Dandrieux, J., Lopez, L., Prakash, N., & Mansfield, C. (2019). Treatment response and long term follow up in nineteen dogs diagnosed with chronic enteropathy in Australia. Australian Veterinary Journal. https://doi.org/10.1111/avj.12846

  • Dandrieux, J., & Mansfield, C. (2019). Chronic enteropathy in canines: Prevalence, impact and management strategies. Veterinary Medicine: Research and Reports, 10, 203–214. https://doi.org/10.2147/vmrr.s162774

  • Dupouy-Manescau, N., Méric, T., Sénécat, O., Drut, A., Valentin, S., Leal, R., & Hernandez, J. (2024). Updating the classification of chronic inflammatory enteropathies in dogs. Animals, 14. https://doi.org/10.3390/ani14050681

  • Economu, L., Chang, Y., Priestnall, S., & Kathrani, A. (2021). The effect of assisted enteral feeding on treatment outcome in dogs with inflammatory protein-losing enteropathy. Journal of Veterinary Internal Medicine, 35, 1297–1305. https://doi.org/10.1111/jvim.16125

  • Febo, E., Crisi, P., Oddi, S., Pietra, M., Galiazzo, G., Piscitelli, F., Gramenzi, A., Di Prinzio, R., Di Tommaso, M., Bernabò, N., Bisogno, T., Maccarrone, M., & Boari, A. (2021). Circulating endocannabinoids as diagnostic markers of canine chronic enteropathies: A pilot study. Frontiers in Veterinary Science, 8. https://doi.org/10.3389/fvets.2021.655311

  • Freiche, V., Dossin, O., Leclerc, A., Mougeot, I., Laxalde, J., Roy, O., Biourge, V., & German, A. (2025). An extensively hydrolysed protein-based extruded diet in the treatment of dogs with chronic enteropathy and at least one previous diet-trial failure: A pilot uncontrolled open-label study. BMC Veterinary Research, 21. https://doi.org/10.1186/s12917-025-04528-y

  • Fritsch, D., Wernimont, S., Jackson, M., MacLeay, J., & Gross, K. (2022). A prospective multicenter study of the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Veterinary Research, 18. https://doi.org/10.1186/s12917-022-03302-8

  • Gałęcki, R., Hanuszewska-Dominiak, M., & Kaczmar, E. (2024). Edible insects as a source of dietary protein for companion animals with food responsive enteropathies—Perspectives and possibilities. Polish Journal of Veterinary Sciences, 27(2), 309–318. https://doi.org/10.24425/pjvs.2024.149361

  • Glanemann, B., Seo, Y., Priestnall, S., Garden, O. A., Kilburn, L., Rossoni-Serão, M., Segarra, S., Mochel, J., & Allenspach, K. (2021). Clinical efficacy of prebiotics and glycosaminoglycans versus placebo in dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study. PLoS ONE, 16. https://doi.org/10.1101/2021.04.13.439608

  • Harris, J., Parnell, N., Griffith, E., & Saker, K. (2017). Retrospective evaluation of the impact of early enteral nutrition on clinical outcomes in dogs with pancreatitis: 34 cases (2010–2013). Journal of Veterinary Emergency and Critical Care, 27, 425–433. https://doi.org/10.1111/vec.12612

  • Heilmann, R., & Steiner, J. (2018). Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs. Journal of Veterinary Internal Medicine, 32, 1495–1508. https://doi.org/10.1111/jvim.15247

  • Higueras, C., Escudero, R., Rebolé, A., García-Sancho, M., Rodríguez-Franco, F., Sainz, Á., & Rey, A. (2023). Changes in faecal and plasma amino acid profile in dogs with food-responsive enteropathy as indicators of gut homeostasis disruption: A pilot study. Veterinary Sciences, 10. https://doi.org/10.3390/vetsci10020112

  • Higueras, C., Rey, A., Escudero, R., Díaz-Regañón, D., Rodríguez-Franco, F., García-Sancho, M., Agulla, B., & Sainz, Á. (2021). Short-chain and total fatty acid profile of faeces or plasma as predictors of food-responsive enteropathy in dogs: A preliminary study. Animals, 12. https://doi.org/10.3390/ani12010089

  • Hodel, S., Brugger, D., & Kook, P. (2024). Long-term evaluation of the initial response to therapy in 60 dogs with chronic inflammatory enteropathy. Journal of Veterinary Internal Medicine, 38, 2444–2453. https://doi.org/10.1111/jvim.17161

  • Holmberg, J., Pelander, L., Ljungvall, I., Harlos, C., Spillmann, T., & Häggström, J. (2022). Chronic enteropathy in dogs—Epidemiologic aspects and clinical characteristics of dogs presenting at two Swedish animal hospitals. Animals, 12. https://doi.org/10.3390/ani12121507

  • Ing, N., & Steiner, J. (2024). The use of diets in the diagnosis and treatment of common gastrointestinal diseases in dogs and cats. Advances in Experimental Medicine and Biology, 1446, 39–53. https://doi.org/10.1007/978-3-031-54192-6_3

  • Jackson, M., & Jewell, D. (2018). Balance of saccharolysis and proteolysis underpins improvements in stool quality induced by adding a fiber bundle containing bound polyphenols to either hydrolyzed meat or grain-rich foods. Gut Microbes, 10, 298–320. https://doi.org/10.1080/19490976.2018.1526580

  • Jugan, M. (2020). Dietary therapy as a treatment option for dogs with chronic enteropathies. Veterinary Record, 186, 23–25. https://doi.org/10.1136/vr.m20

  • Kathrani, A. (2020). Dietary and nutritional approaches to the management of chronic enteropathy in dogs and cats. Veterinary Clinics of North America: Small Animal Practice. https://doi.org/10.1016/j.cvsm.2020.09.005

  • Kawano, K., Shimakura, H., Nagata, N., Masashi, Y., Suto, A., Suto, Y., Uto, S., Ueno, H., Hasegawa, T., Ushigusa, T., Nagai, T., Arawatari, Y., Miyaji, K., Ohmori, K., & Mizuno, T. (2016). Prevalence of food-responsive enteropathy among dogs with chronic enteropathy in Japan. Journal of Veterinary Medical Science, 78, 1377–1380. https://doi.org/10.1292/jvms.15-0457

  • Makielski, K., Cullen, J., O’Connor, A., & Jergens, A. (2018). Narrative review of therapies for chronic enteropathies in dogs and cats. Journal of Veterinary Internal Medicine, 33, 11–22. https://doi.org/10.1111/jvim.15345

  • Manchester, A., Dow, S., Chow, L., Gagne, J., & Lappin, M. (2023). Efficacy of an elemental diet in achieving clinical remission in dogs with chronic enteropathy. Journal of Veterinary Internal Medicine, 37, 2322–2333. https://doi.org/10.1111/jvim.16846

  • Mandigers, P., Biourge, V., van den Ingh, T., Ankringa, N., & German, A. (2010). A randomized, open-label, positively-controlled field trial of a hydrolyzed protein diet in dogs with chronic small bowel enteropathy. Journal of Veterinary Internal Medicine, 24(6), 1350–1357. https://doi.org/10.1111/j.1939-1676.2010.0632.x

  • Margrey, C., Rollins, A., Tolbert, M., Murphy, M., Zhu, X., & Schmid, S. (2025). Characteristics, nutritional recommendations, and medical interventions of 58 dogs with protein-losing enteropathy presenting to a veterinary nutrition service. Journal of Veterinary Internal Medicine, 39. https://doi.org/10.1111/jvim.70247

  • Martello, E., Costale, A., Ferrarini, F., Vergnano, D., Guidetti, G., & Meineri, G. (2025). Liquid hydrolyzed fish protein (anchovy) in the canine diet: A focus on gut fermentation and fecal quality. Veterinary Sciences, 12. https://doi.org/10.3390/vetsci12080779

  • Marwein, S., Rajesh, J., Rose, K., Kar, P., Behera, S., Tolenkhomba, T., & Sarma, K. (2025). Review on canine chronic enteropathy. International Journal of Bio-resource and Stress Management. https://doi.org/10.23910/1.2025.6189

  • Matricoti, I., & Noli, C. (2018). An open label clinical trial to evaluate the utility of a hydrolysed fish and rice starch elimination diet for the diagnosis of adverse food reactions in dogs. Veterinary Dermatology, 29, 408–e134. https://doi.org/10.1111/vde.12680

  • Moreno, A., Parker, V., Winston, J., & Rudinsky, A. (2022). Dietary fiber aids in the management of canine and feline gastrointestinal disease. Journal of the American Veterinary Medical Association, 1–13. https://doi.org/10.2460/javma.22.08.0351

  • Myers, M., Martinez, S., Shiroma, J., Watson, A., & Hostutler, R. (2023). Prospective evaluation of low-fat diet monotherapy in dogs with presumptive protein-losing enteropathy. Journal of the American Animal Hospital Association, 59(2), 74–84. https://doi.org/10.5326/jaaha-ms-7248

  • Nagata, N., Ohta, H., Yokoyama, N., Teoh, Y., Nisa, K., Sasaki, N., Osuga, T., Morishita, K., & Takiguchi, M. (2020). Clinical characteristics of dogs with food-responsive protein-losing enteropathy. Journal of Veterinary Internal Medicine, 34, 659–668. https://doi.org/10.1111/jvim.15720

  • Pilla, R., Guard, B., Steiner, J., Gaschen, F., Olson, E., Werling, D., Allenspach, K., Schmitz, S., & Suchodolski, J. (2019). Administration of a synbiotic containing Enterococcus faecium does not significantly alter fecal microbiota richness or diversity in dogs with and without food-responsive chronic enteropathy. Frontiers in Veterinary Science, 6. https://doi.org/10.3389/fvets.2019.00277

  • Rodrigues, S. D., Mendoza, B., Dias, M. J., Santos, N. S., Hebert, M., Bettin, E., Signorelli, F., Procoli, F., Hernandez, J., & Leal, R. O. (2025). Association of diet with treatment response in dogs with chronic enteropathy: A retrospective multicenter study. Journal of Veterinary Internal Medicine, 39(3), e70071. https://doi.org/10.1111/jvim.70071

  • Rossi, G., Cerquetella, M., Gavazza, A., Galosi, L., Berardi, S., Mangiaterra, S., Mari, S., Suchodolski, J., Lidbury, J., Steiner, J., & Pengo, G. (2020). Rapid resolution of large bowel diarrhea after the administration of a combination of a high-fiber diet and a probiotic mixture in 30 dogs. Veterinary Sciences, 7. https://doi.org/10.3390/vetsci7010021

  • Rudinsky, A., Howard, J., Bishop, M., Sherding, R., Parker, V., & Gilor, C. (2017). Dietary management of presumptive protein-losing enteropathy in Yorkshire terriers. Journal of Small Animal Practice, 58, 103–108. https://doi.org/10.1111/jsap.12625

  • Schmitz, S., Glanemann, B., Garden, O., Brooks, H., Chang, Y., Werling, D., & Allenspach, K. (2015). A prospective, randomized, blinded, placebo-controlled pilot study on the effect of Enterococcus faecium on clinical activity and intestinal gene expression in canine food-responsive chronic enteropathy. Journal of Veterinary Internal Medicine, 29, 533–543. https://doi.org/10.1111/jvim.12563

  • Simpson, K., Miller, M., Loftus, J., Rishniw, M., Frederick, C., & Wakshlag, J. (2023). Randomized controlled trial of hydrolyzed fish diets in dogs with chronic enteropathy. Journal of Veterinary Internal Medicine, 37, 2334–2343. https://doi.org/10.1111/jvim.16844

  • Tamura, Y. (2025). Chronic enteropathy and vitamins in dogs. Animals, 15. https://doi.org/10.3390/ani15050649

  • Tinsley, J., Griffin, C., Sheinberg, G., Griffin, J., Cross, E., Gagne, J., & Romero, A. (2023). An open-label clinical trial to evaluate the efficacy of an elemental diet for the diagnosis of adverse food reactions in dogs. Veterinary Dermatology. https://doi.org/10.1111/vde.13198

  • Tolbert, M., Murphy, M., Gaylord, L., & Witzel-Rollins, A. (2022). Dietary management of chronic enteropathy in dogs. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13471

  • Tørnqvist-Johnsen, C., Campbell, S., Gow, A., Bommer, N., Salavati, S., & Mellanby, R. (2019). Investigation of the efficacy of a dietetic food in the management of chronic enteropathies in dogs. Veterinary Record, 186, 26–26. https://doi.org/10.1136/vr.105172

  • Treese, J., Nolte, I., & Bach, J. (2021). Chronic enteropathy in dogs – Retrospective case analysis and results of an owner survey. Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, 49, 94–103. https://doi.org/10.1055/a-1354-0630

  • Trewin, I., & Kathrani, A. (2023). Pre-illness dietary risk factors in dogs with chronic enteropathy. Journal of Veterinary Internal Medicine, 37, 2093–2101. https://doi.org/10.1111/jvim.16872

  • Vecchiato, C., Bardhi, A., Tardo, A., Foietta, L., Biagi, G., Sabetti, M., Fracassi, F., Barbarossa, A., & Pietra, M. (2025). Serum 25(OH)D reflects clinical characterization in dogs with chronic enteropathies. Frontiers in Veterinary Science, 12. https://doi.org/10.3389/fvets.2025.1677939

  • Vuori, K., Hemida, M., Moore, R., Salin, S., Rosendahl, S., Anturaniemi, J., & Hielm-Björkman, A. (2023). The effect of puppyhood and adolescent diet on the incidence of chronic enteropathy in dogs later in life. Scientific Reports, 13. https://doi.org/10.1038/s41598-023-27866-z

  • Walker, D., Knuchel-Takano, A., McCutchan, A., Chang, Y., Downes, C., Miller, S., Stevens, K., Verheyen, K., Phillips, A., Miah, S., Turmaine, M., Hibbert, A., Steiner, J., Suchodolski, J., Mohan, K., Eastwood, J., Allenspach, K., Smith, K., & Garden, O. (2013). A comprehensive pathological survey of duodenal biopsies from dogs with diet-responsive chronic enteropathy. Journal of Veterinary Internal Medicine, 27(4), 862–874. https://doi.org/10.1111/jvim.12093

  • Wang, S., Martins, R., Sullivan, M., Friedman, E., Misic, A., El-Fahmawi, A., De Martinis, E., O’Brien, K., Chen, Y., Bradley, C., Zhang, G., Berry, A., Hunter, C., Baldassano, R., Rondeau, M., & Beiting, D. (2019). Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids. Microbiome, 7. https://doi.org/10.1186/s40168-019-0740-4

  • Wennogle, S., Stockman, J., & Webb, C. (2021). Prospective evaluation of a change in dietary therapy in dogs with steroid-resistant protein-losing enteropathy. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13334

  • Wg, G. (1994). Nutritional management of gastrointestinal tract diseases of dogs and cats. Journal of Nutrition, 124, 2663S–2669S. https://doi.org/10.1093/jn/124.suppl_12.2663s

  • Yeo, E. (2017). The role of hydrolysed diets in diagnosing and treating canine enteropathy. Veterinary Nurse, 8, 246–251. https://doi.org/10.12968/vetn.2017.8.5.246

 

Compare Diet Strategies for Food-Responsive Enteropathy in Dogs

Selecting the appropriate diet depends on disease severity, underlying mechanisms, and clinical response.

Explore structured decision pathways: https://www.vetfarmacy.com/decision-frameworks/low-fat-hydrolyzed-fresh-diet

bottom of page